Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years (male or female) who fully understand the study and agree to take part by signing a consent form
• People who have at least one tumour that can be measured using standard imaging guidelines (known as RECIST 1.1)
• People who have been confirmed by tissue or cell testing to have a lung neuroendocrine tumour (typical or atypical carcinoid), with at least one specific tumour marker showing positive on laboratory testing
• People who have not previously received any systemic (whole-body) treatment for this cancer — although early-stage chemotherapy given before or after surgery is allowed, provided the cancer came back or got worse at least 6 months after that treatment ended
• People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale (or up to 2 for people who have had a limb amputation)
• People whose doctors expect them to survive at least 12 weeks
• People whose blood test results meet specific standards for blood cell counts, liver function, and kidney function, without having had a blood transfusion in the 14 days before testing
• People of childbearing potential who agree to use effective contraception during the study and for 6 months after the last dose of study medication

Who may not be able to join:

• People who have previously been treated with surufatinib or other drugs that target blood vessel growth
• People who have received any systemic cancer treatment (such as chemotherapy, radiotherapy, immunotherapy, or targeted therapy) within the 4 weeks before joining
• People who have taken part in another unapproved or experimental drug trial and received that trial drug within the 4 weeks before joining
• People who have had surgery or an invasive procedure affecting wound healing within the 4 weeks before joining (routine procedures such as IV line insertion or drainage are generally excepted — confirm with trial site)
• People whose blood clotting test results are above certain levels (confirm with trial site)
• People with clinically significant abnormal levels of electrolytes (salts in the blood), as judged by the treating doctor
• People with high blood pressure that cannot be controlled with medication, specifically where the reading remains at or above 140/90 mmHg
• People who are unable to swallow tablets or who have a condition that would prevent the study drug from being properly absorbed
• People who currently have active stomach or bowel ulcers, ulcerative colitis, or other conditions that the doctor considers may cause gastrointestinal bleeding or perforation, or who have tumours with active bleeding
• People who have had significant bleeding episodes, vomiting of blood, or black or bloody stools within the past 3 months, or who have coughed up more than 5 mL of fresh blood in the past 4 weeks, or who have had a stroke or similar blood clot event within the past 12 months
• People who have had a heart attack, severe chest pain, or heart bypass surgery within the past 6 months, or who have significant heart failure, certain irregular heart rhythms requiring medication, or reduced heart pumping function
• People who have had another cancer within the past 5 years, except for certain fully treated skin cancers or cervical carcinoma in situ
• People with active or uncontrolled serious infections, including known HIV, active hepatitis B, active hepatitis C, or other forms of hepatitis or cirrhosis
• People with active brain metastases or cancer spread to the lining of the brain — although people with previously treated, stable brain metastases (stable for at least 2 weeks, no new growth, and off steroids for at least 3 days) or small, symptom-free brain metastases may be considered (confirm with trial site)
• People who still have side effects from previous cancer treatment that have not improved to a mild level (grade 2 or lower), except for hair loss or low lymphocyte counts, which are permitted
• People who are pregnant or breastfeeding
• People who have received blood transfusions, blood products, or certain blood-boosting medications (such as albumin or G-CSF) within the 14 days before joining
• People whose urine protein levels are elevated above a certain threshold on testing
• People who the treating doctor considers unsuitable for any clinical or other reason

Important: Always verify eligibility with the trial site directly before applying.